Formulation of a modified release metformin. HCl matrix tablet: influence of some hydrophilic polymers on release rate and in-vitro evaluation by Rojas, John et al.
*Correspondence: T. P. John Rojas. School of Pharmaceutical Chemistry, The 





leBrazilian Journal of 
Pharmaceutical Sciences
vol. 47, n. 3, jul./sep., 2011
Formulation of a modified release metformin.HCl matrix tablet: 
influence of some hydrophilic polymers on release rate and in-vitro 
evaluation
John Rojas*, Cesar González, Carolina Rico, Oswaldo Saez
School of Pharmaceutical Chemistry, The University of Antioquia
Metformin hydrochloride is an antidiabetic agent which improves glucose tolerance in patients with type 
2 diabetes and reduces basal plasma levels of glucose. In this study, a simplex centroid experimental 
design with 69 runs was used to select the best combination of some hydrophilic polymers that rendered 
a 24 h in-vitro release profile of metformin.HCl. The Korsmeyer–Peppas model was used to model the 
dissolution profiles since it presented the best fit to the experimental data. Further, a cubic model predicted 
the best formulation of metformin.HCl containing polyvinyl pyrrolidone, ethyl cellulose, hydroxypropyl 
methyl cellulose, carrageenan, sodium alginate, and gum arabic at 6.26, 68.7, 6.26, 6.26, 6.26 and 6.26 % 
levels, respectively. The validation runs confirmed the accuracy of the cubic model with six components 
for predicting the best set of components which rendered a once-a-day modified release hydrophilic 
matrix tablet in compliance with the USP specifications.
Uniterms: Metformin/release profile. Metformin.HCl/modified release/in-vitro evaluation. Hydrophilic 
polymers/influence/drugs release. Korsmeyer-Peppas model/dissolution profiles.
O cloridrato de metformina é um agente antidiabético que melhora a tolerância à glicose em 
pacientes com diabetes tipo 2 e reduz os níveis plasmáticos basais de glicose. Neste estudo, um 
projeto experimental do tipo “centróide simplex” com 69 tomadas foi usado para selecionar a melhor 
combinação de alguns polímeros hidrofílicos que gerou um perfil de liberação da metformina.HCl 
de 24 horas. O modelo Korsmeyer-Peppas foi usado para modelar os perfis de dissolução, uma vez 
que apresentou os melhores ajustes aos dados experimentais. Além disso, um modelo cúbico previu 
a melhor formulação de metformina.HCl sendo aquela contendo polivinilpirrolidona, etilcelulose, 
hidroxipropilmetil celulose, carragena, alginato de sódio e goma arábica nos níveis 6.26, 68.7, 6.26, 
6.26, 6.26 e 6.26 %, respectivamente. As corridas de validação confirmaram a precisão do modelo cúbico 
com os seis componentes para prever o melhor conjunto de componentes que originou uma libertação 
do tipo “uma vez ao dia” em conformidade com as especificações da USP, a partir de comprimidos  
matriciais.
Unitermos: Metformina/perfil de liberação. Cloridrato de metformina/liberação modificada/in-vitro 
evaluation. Polímeros hidrofílicos/influência/liberação de fármacos. Modelo Korsmeyer-peppas/perfil 
de dissolução.
INTRODUCTION
It is estimated that by 2025 around 300 million 
people will be diagnosed with diabetes (Ritu et al., 2009; 
Jain, Gupta, 2009). Metformin hydrochloride (MH) is 
an oral anti-hyperglycemic drug used in the treatment of 
Type 2 diabetes in patients who cannot manage the disease 
with only diet and exercise (Chouldhury, Kar, 2008). It 
improves glucose tolerance by lowering both basal and 
postprandial glucose by decreasing intestinal absorption 
of glucose, decreasing hepatic gluconeogenesis, incre-
asing glycogenesis, lipogenesis and glucose uptake by 
adipocytes and muscle cells (Choudhury et al., 2008; 
Stepensky et al., 2002). MH is a highly water soluble drug 
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(0.5 g/mL) administered up to 2.5 g/day in three separate 
doses given with meals to minimize possible gastrointes-
tinal side effects such as anorexia, abdominal discomfort, 
nausea, and diarrhea (Gouldson, Deasy, 1997). However, 
food also decreases the absorption of the drug (Hu et al., 
2006). The presence of side effects and the need for three-
times-a-day administration could reduce patient complian-
ce and hinder successful treatment (Mandal et al., 2007). 
MH does not produce lactic acidosis as seen in other 
biguanide drugs such as phenformin and buformin (Tucker 
et al., 1981). Further, MH does not bind to plasma proteins 
and the elimination of the unchanged drug mainly occurs 
by active tubular secretion through the kidneys. A single 
dose of 500 mg of an immediate and modified release MH 
showed higher plasma concentrations for the latter in the 
steady-state (Karttunen et al., 1983). A single immediate 
release dose of MH exhibits a flip-flop model and a bio-
availability of about 61%. The tmax and t1/2 of MH after a 
single immediate release oral dose of 500 mg was ~2 h and 
2.6 h, respectively (Pentikainen et al., 1979). However, a 
250 mg sustained-release MH pellet showed a tmax of 7.3 h 
and t1/2 of 8.3 h and a 165% increase in bioavailability in 
comparison to the immediate release formulation and 
thus, tmax depended on the dose. For instance, tmax was 2.2 h 
and 1.5 h for an immediate release dose of 0.5 and 1.5 g, 
respectively (Tucker, 1981). Further, ~20% of the single 
immediate release dose is recovered in faeces, indicating 
saturable absorption and low absorption in the terminal 
segment of the colon (Lian-Dong et al., 2006; Gusler et 
al., 2001; Pentikainen, 1986). This problem creates the 
need for a modified release device to modulate the release 
and hence, the absorption of MH. Thus, a modified release 
system allows for achieving an optimal therapy, improving 
patient compliance and safety, reducing dose dumping, 
plasma fluctuations and the incidence of side effects. Corti 
and collaborators achieved a sustained-release MH matrix 
based on Eudragit L100-55, HPMC and b-cyclodextrin 
which released up to 60% of the drug within 5 h (Corti 
et al., 2008). 
Hydrophilic matrices are composed of hydrophilic 
polymers, an active ingredient and other excipients ho-
mogeneously distributed in a three dimensional network. 
Several factors affect the drug release from a hydrophilic 
matrix (Conte et al., 1988; Colombo et al., 1999). These 
factors are the drug solubility, polymer swelling, polymer 
erosion, drug dissolution/diffusion characteristics, distri-
bution of drug within the polymer matrix and proportion 
and geometry of the system (Wu, Zhou, 1998; Zhou, Wu, 
1997; Adrover et al., 1996). The absorption of solvent, as 
well as the drug release, also depends on the viscoelastic 
properties of the polymer (Crank, 1975).
If the network of the matrix is seen as a mesh, large 
spaces can be defined as access points for the diffusion 
of drugs (Maulin, Ben-Avhraham, 1987). In non-porous 
matrices, swelling occurs first, moving and expanding the 
dry glassy core portion of the swollen matrix (Crank, 1975; 
Colombo et al., 1999). However, for porous systems, drug 
release also depends on the porosity of the matrix and drug 
dissolution/diffusion through the pores. This behavior is 
prevalent in hydrophobic porous matrices (Barry et al., 
1979; Colombo et al., 1999). Non-porous systems have 
no defined pores and the molecules diffuse through the 
mesh of the matrix (Robert et al., 1985). In the case of 
poorly soluble drugs, the diffusion front may appear be-
tween the outside of the swollen matrix, where the drug 
is completely dissolved, and the inside, where the drug 
is still undissolved. Drug release in swellable matrices is 
controlled by the diffusion coefficient and the swelling 
process (Grassi, 2003). 
In a swellable matrix, swelling of the polymer matrix 
and drug loading affect the drug release kinetics (Grassi et 
al., 2003). The swelling behavior depends largely on the 
number of intermolecular bonds per volume of polymer. 
For neutral polymers, the amount of solvent absorbed 
depends on the chemical affinity of the polymer for the 
solvent and on the elastic properties of the swollen poly-
mer network. In the case of charged polymers, swelling 
depends on the ionic strength (Ricka, Tanaka, 1984; 
Okazaki et al., 1996). In fact, the chains of a cross-linked 
polyelectrolyte assume a modified conformation in pure 
water, while this conformation is precluded in aqueous 
salt solutions, due to the electrostatic interactions between 
polymer charges and mobile ions present in the solution 
(Tanaka et al., 1986). 
In the present study, formulations of hydrophilic 
matrixes composed of MH, ethylcellulose, HPMC, carra-
geenan, sodium alginate, gum arabic and PVP were prepa-
red by wet granulation followed by tableting to achieve a 
once-a-day controlled release preparation. This provides a 
lower but controlled drug concentration over an extended 
period of time (24 h). The resulting dissolution profiles 
and release kinetics of the matrices were also evaluated.
MATERIAL AND METHODS
Material
Ethylcellulose standard 7 with ethoxyl content of 
48-49.5% (lot TS051977) was donated by Colorcon, Inc. 
Harleysville, PA, USA. HPMC Type 2919 with methoxyl 
content of 28–30% and hydroxypropyl content of 7–12% 
(lot 506825) was obtained from Dow Wolff Cellulosics 
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Midland, MI, USA). K-carrageenan (lot 217882), and 
gum Arabic (lot 104K0151) were purchased from Bell 
Chem Corp., Longwood, FL, USA.  Sodium alginate (lot 
990972) and PVP K-30 (lot 0911106) were purchased 
from Sigma-Aldrich, St. Louis, MO, USA. Monobasic 
potassium phosphate (lot 8N117059B) and NaOH (lot 
B0244398) were obtained from Carlo Erba, Milan, Italy 
and Merck, Darmstadt, Germany, respectively.
Methods
Preparation of Matrix Compacts
Powder mixtures of ~10 g were prepared in a mortar 
a pestle using a 70% ethanol solution as a wetting agent. 
The wet samples were then granulated on an oscillating 
granulator equipped with a size 40 mesh (Riddhi Pharma 
Machinery, Gulabnagar, India), followed by drying at 
room temperature for 14 h until reaching a moisture con-
tent of less than 3%. The dry samples were then granulated 
on an oscillating granulator using a size 40 and 60 mesh, 
consecutively. Cylindrical compacts, each Weighing 
~1750 mg were then made on a rotary tablet press (512-1, 
FJ Stokes Manufacturer Corporation, Philadelphia, PA, 
USA) equipped with a 13 mm diameter concave punches 
and die set. The compression force was controlled to give 
a compact porosity of ~ 0.3 (compact solid fraction of 0.7). 
The uniformity of the dose (Table I) was assessed on three 
compacts of each formulation by grinding 3 compacts 
from each formulation in a mortar, followed by dispersing 
the powder in distilled water and filtering through a 0.45 
µm membrane. Dilutions of this solution were conducted 
to achieve a concentration of 8 µg/mL. The absorbance 
of this solution was measured at 232 nm and the resulting 
concentration was interpolated from a calibration curve. 
The United States Pharmacopoeia (USP34/NF29) speci-
fication for  uniformity of dose is from 90 to 100%.
In-vitro dissolution studies
Matrixes containing 750 mg of MH were agitated at 
100 rpm in 1000 mL of phosphate buffer pH 6.8 at 37 °C 
in a dissolution basket assembly (VARIAN dissolutor, 
VK7000, Palo Alto, CA, USA). Five milliliter aliquots 
were withdrawn periodically with immediate replace-
ment of the dissolution medium and subsequent filtration 
through a 0.45 µm filter. Samples were analyzed by UV 
spectroscopy (Shimadzu UV-1700, Kyoto, Japan) at 
232 nm (USP34/NF29).
Simplex centroid mixture design
A “simplex centroid” experimental mixture design 
with 6 components (ethyl cellulose, HPMC, PVP, carra-
geenan, sodium alginate and gum arabic) and 69 runs was 
employed (Table I). The two dependent variables were 
release rate (k) and release order (n). The non-linear fitting 
model was conducted by using the Statgraphics software 
(StatPoint, Inc. Warrenton, VA). The coefficients of the 
model estimate the variation in the experimental para-
meters. The results were analyzed either as an analysis of 
the coefficients of the various polymers, or as an analysis 
of variance (ANOVA). Preliminary fitting of the data to 
the zero order, first order, Higuchi, Hixson-Crowell and 
Korsmeyer-Peppas (KP) determined the latter as the most 
suitable release model based on the comparison of the re-
levant correlation coefficients and thus, only results from 
this model were included in this study.
Modeling of dissolution profiles




= k*tn  (1)
where M∞ is the amount of drug released at infinite time, 
k is the rate constant of drug release and n is the exponent 
that characterizes the process of release. If the diffusion 
process is Fickian, n is equal to 0.5, 0.45 and 0.43 for thin 
films, cylindrical and spherical matrices, respectively. 
When n exceeds these thresholds, the release is non-
Fickian (Ritger, Peppas, 1987). The release mechanism is 
given once the polymer chains contact the solvent and the 
chains are reoriented to achieve a new equilibrium condi-
tion (Siepman, Peppas, 2001). The time required for this 
reorganization is called polymer relaxation time (tr). If tr 
is much smaller than the diffusion time td required for the 
release, the process is then Fickian. When tr@td, solvent ab-
sorption is not Fickian or anomalous (Grassi et al., 1998). 
Validation of optimization model
A cubic model including interaction terms were 
generated for k and n using the multiple linear regression 
analysis of the Minitab software (State College, PA). 
Statistical validity of the model was established on the 
basis of the ANOVA test. Further, the feasibility and grid 
search were used to find the composition of the optimum 
formulations. Ten check points were also selected based 
on the criteria of optimum formulation by intensive grid 
search to validate the experimental design and the model. 
The formulations corresponding to the optimal formula-
tion were prepared and evaluated for the two responses. 
Subsequently, the experimental data of the ten check points 
and the optimal formulation were quantitatively compared 
with that of the predicted values.
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TABLE I - Simplex centroid matrix and responses obtained according to the Korsmeyer-Peppas (KP) model
F PVP EC HPMC C SA GA K N R2 UD(%)
F1 0.25 0.25 0.00 0.25 0.00 0.25 0.335 0.340 0.9505 102.1
F2 0.00 0.25 0.25 0.25 0.25 0.00 0.289 0.402 0.9708 97.6
F3 0.58 0.08 0.08 0.08 0.08 0.08 0.844 0.073 0.9861 95.6
F4 0.00 0.25 0.25 0.00 0.25 0.25 0.304 0.396 0.9775 91.8
F5 0.33 0.00 0.00 0.33 0.00 0.33 0.335 0.369 0.9793 102.6
F6 0.17 0.17 0.17 0.17 0.17 0.17 0.291 0.414 0.9683 101.4
F7 0.50 0.00 0.00 0.00 0.00 0.50 0.287 0.411 0.9576 100.4
F8 0.00 0.00 0.00 0.50 0.00 0.50 0.297 0.396 0.9631 100.5
F9 0.25 0.00 0.00 0.25 0.25 0.25 0.206 0.497 0.9906 98.3
F10 0.00 0.00 0.25 0.25 0.25 0.25 0.282 0.391 0.976 100.2
F11 0.00 0.00 0.33 0.33 0.00 0.33 0.244 0.445 0.9941 100.1
F12 0.25 0.25 0.00 0.25 0.25 0.00 0.702 0.129 0.9412 93.7
F13 0.50 0.00 0.00 0.50 0.00 0.00 0.821 0.042 0.9792 96.5
F14 0.00 0.33 0.33 0.00 0.33 0.00 0.257 0.435 0.9908 95.2
F15 0.00 0.00 0.50 0.00 0.00 0.50 0.254 0.442 0.976 94.3
F16 0.00 0.00 0.50 0.50 0.00 0.00 0.260 0.435 0.985 98.7
F17 0.20 0.20 0.00 0.20 0.20 0.20 0.396 0.317 0.9306 101.3
F18 0.00 0.33 0.33 0.00 0.00 0.33 0.170 0.505 0.9891 99.2
F19 0.00 0.33 0.33 0.33 0.00 0.00 0.186 0.529 0.9975 94.9
F20 0.25 0.25 0.25 0.25 0.00 0.00 0.251 0.452 0.9753 100.4
F21 0.25 0.00 0.25 0.25 0.25 0.00 0.368 0.314 0.9976 95.2
F22 0.20 0.20 0.20 0.00 0.20 0.20 0.213 0.487 0.996 98.1
F23 0.00 0.25 0.00 0.25 0.25 0.25 0.238 0.451 0.9994 95.9
F24 0.00 0.50 0.50 0.00 0.00 0.00 0.198 0.510 0.9992 93.4
F25 0.25 0.00 0.25 0.00 0.25 0.25 0.274 0.408 0.9882 92.1
F26 0.00 0.33 0.00 0.00 0.33 0.33 0.175 0.548 0.9985 96.1
F27 0.33 0.33 0.00 0.00 0.00 0.33 0.362 0.348 0.9837 95.8
F28 0.08 0.08 0.08 0.08 0.58 0.08 0.359 0.322 0.9929 105.7
F29 0.00 0.00 0.33 0.33 0.33 0.00 0.241 0.447 0.9939 99.5
F30 0.33 0.00 0.00 0.00 0.33 0.33 0.195 0.514 0.9996 94.8
F31 0.00 0.00 0.33 0.00 0.33 0.33 0.282 0.402 0.9956 97.8
F32 0.08 0.08 0.08 0.08 0.08 0.58 0.291 0.387 0.9977 98.1
RESULTS AND DISCUSSION
In-vitro dissolution studies
Table I lists the composition of 69 trial formulations 
prepared with different combinations of polymers such as 
ethyl cellulose, HPMC, PVP, carrageenan, sodium alginate, 
and gum arabic. The data obtained were modeled according 
to the KP model because it was the only model that rendered 
the best fit (R2> 0.9991) to the release data of MH except 
for formulation 40 (R2> 0.8753). Preliminary fitting to other 
models such as zero order, first order, Hixson-Crowell and 
Higuchi failed to give R2 higher than 0.85. The parameters k 
and n obtained from the KP model are also shown in Table I. 
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F PVP EC HPMC C SA GA K N R2 UD(%)
F33 0.08 0.08 0.08 0.58 0.08 0.08 0.334 0.344 0.9842 100.4
F34 0.00 0.50 0.00 0.50 0.00 0.00 0.659 0.126 0.9919 103.1
F35 0.20 0.00 0.20 0.20 0.20 0.20 0.248 0.443 0.9948 102.3
F36 0.00 0.00 1.00 0.00 0.00 0.00 0.243 0.446 0.9904 105.2
F37 0.25 0.00 0.25 0.25 0.00 0.25 0.312 0.356 0.9823 97.3
F38 0.00 0.20 0.20 0.20 0.20 0.20 0.263 0.423 0.996 104.5
F39 0.20 0.20 0.20 0.20 0.20 0.00 0.277 0.391 0.993 99.2
F40 0.50 0.00 0.50 0.00 0.00 0.00 0.527 0.222 0.8753 106.8
F41 0.33 0.00 0.33 0.00 0.33 0.00 0.290 0.400 0.9919 100.1
F42 0.33 0.33 0.00 0.00 0.33 0.00 0.907 0.026 0.9656 105.2
F43 0.33 0.33 0.33 0.00 0.00 0.00 0.359 0.346 0.9441 102.1
F44 0.00 0.00 0.50 0.00 0.50 0.00 0.269 0.400 0.9936 104.3
F45 0.00 0.33 0.00 0.33 0.00 0.33 0.338 0.346 0.9965 101.6
F46 0.50 0.50 0.00 0.00 0.00 0.00 1.000 0.002 0.9998 101.2
F47 0.00 0.50 0.00 0.00 0.50 0.00 0.368 0.313 0.9732 99.5
F48 0.00 1.00 0.00 0.00 0.00 0.00 0.629 0.160 0.9389 103.8
F49 0.00 0.33 0.00 0.33 0.33 0.00 0.949 0.022 0.9924 102.2
F50 0.00 0.25 0.25 0.25 0.00 0.25 0.288 0.411 0.9841 106.5
F51 0.00 0.00 0.00 0.00 1.00 0.00 0.313 0.363 0.983 105.3
F52 0.25 0.25 0.25 0.00 0.00 0.25 0.294 0.388 0.997 103.1
F53 0.33 0.00 0.00 0.33 0.33 0.00 0.927 0.017 0.9989 104.8
F54 0.33 0.00 0.33 0.00 0.00 0.33 0.513 0.232 0.9563 98.2
F55 1.00 0.00 0.00 0.00 0.00 0.00 0.985 0.000 0.9976 106.1
F56 0.00 0.50 0.00 0.00 0.00 0.50 0.320 0.380 0.9727 104.2
F57 0.33 0.33 0.00 0.33 0.00 0.00 0.917 0.044 0.9882 104.9
F58 0.20 0.20 0.20 0.20 0.00 0.20 0.309 0.382 0.9858 103.5
F59 0.00 0.00 0.00 0.00 0.50 0.50 0.286 0.411 0.9851 94.9
F60 0.00 0.00 0.00 1.00 0.00 0.00 0.792 0.067 0.9821 102.5
F61 0.00 0.00 0.00 0.00 0.00 1.00 0.316 0.383 0.9837 106.1
F62 0.25 0.25 0.00 0.00 0.25 0.25 0.718 0.117 0.9746 104.1
F63 0.00 0.00 0.00 0.33 0.33 0.33 0.365 0.339 0.984 102.3
F64 0.00 0.00 0.00 0.50 0.50 0.00 0.524 0.206 0.9962 96.4
F65 0.08 0.58 0.08 0.08 0.08 0.08 0.313 0.380 0.9905 99.8
F66 0.33 0.00 0.33 0.33 0.00 0.00 0.891 0.036 0.9938 105.7
F67 0.50 0.00 0.00 0.00 0.50 0.00 0.733 0.107 0.9707 107.3
F68 0.25 0.25 0.25 0.00 0.25 0.00 0.433 0.290 0.9125 97.4
F69 0.08 0.08 0.58 0.08 0.08 0.08 0.285 0.398 0.9926 99.3
F = formulation; E = ethyl cellulose; SA = sodium alginate; GA = gum arabic; C = carrageenan; HPMC = hydroxypropyl methyl 
cellulose; PVP = Polyvinyl pyrrolidone; k = drug release constant; n = release type; UD = uniformity of the dose
TABLE I - continuation
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The release profile of MH from the single polymers 
is shown in Figure 1. PVP caused the fastest release of 
MH and when this component was present at a high level, 
drug release was also fast. PVP is very soluble in water 
and wets easily when its matrixes come into contact with 
water, leading to quick dissolution and erosion of the 
matrix. By contrast, the HPMC matrix alone rendered the 
slowest drug release. The HPMC matrix hydrates rapidly 
on contact with water to form a gel on the surface of the 
tablet. Soluble drugs such as MH are released primarily 
by diffusion through the gel layer. The matrix compacts 
containing ethyl cellulose in combination with hydrophilic 
polymers presented the mechanism of swelling and ero-
sion, whereas ethyl cellulose alone has a diffusion through 
the pores mechanism. The formulation containing MH and 
pure carrageenan formed a fast eroding gel which could 
have increased the medium viscosity.
The formulation containing MH and sodium algi-
nate also formed a gel when placed in contact with the 
medium, but eroded slowly. The formulation containing 
only gum arabic also formed a gel, but it was less viscose 
than that produced by carrageenan and sodium alginate. 
For swelling and gelling polymers such as HPMC, the 
viscosity of the gel layer around the compact increases 
at higher  hydrogel concentration, slowing the release of 
MH because the gel is formed by closely-packed swollen 
particles. In general, the release rate (k) of the pure poly-
mers with the drug followed the trend:
PVP> Carrageenan> ethylcellulose>sodium alginate 
@gum arabic> HPMC. It is observed that formulations con-
taining sodium alginate (F51) and gum arabic (F61), which 
were the most gelling materials, had similar release rates 
(0.313 and 0.316, respectively). By contrast, the formu-
lation containing only MH and HPMC (F36) yielded the 
slowest release profile. The value of n of this formulation 
indicates that it follows a Fickian release (n = 0.45) which 
coincides with that expected for cylindrical matrices. This 
is the major reason why this polymer is widely used for 
modified release of drugs. Conversely, most formulations 
had an anomalous release which comprises swelling, ero-
sion and disintegration of the matrix. 
Formulations such as F3, F12, F13, F42, F46, F53, 
F57, F62, F66, and F67 containing considerable levels 
of PVP or carrageenan and very low levels of highly 
gelling polymers such as HPMC, exhibited an initial 
burst of the matrix releasing the drug quickly as seen by 
the high k values. This is attributed to the dissolution of 
the drug present initially at the surface of the matrices 
followed by a fast penetration of dissolution media to the 
matrix causing a disruption of its structure. By contrast, 
sodium alginate and gum arabic (which gel and form a 
halo around the area of contact with the aqueous medium) 
release the drug more slowly and their profiles fall within 
the USP range.
For gum arabic, HPMC and ethylcellulose, the pre-
sence of cross-links among polymer chains is responsible 
for the wetting of the polymer with the liquid, resulting in 
the expansion of the network resembling a sponge soaked 
in water. If cross-linking among the polymer chains have 
a covalent nature the network does not change with time. 
On the contrary, if the interactions are Van der Waals, 
dipole-dipole, hydrophobic or hydrogen bonding type, 
the polymer chains are not rigidly connected, resulting in 
polymer burst/erosion as occurred for PVP and carragee-
nan (Barry, Meyer, 1979). Since the method of preparation 
of these matrices involves wet granulation and tableting, 
the resulting matrixes can be considered porous systems 
and MH which is a water soluble drug is more likely to 
diffuse through the pores, rather than through the mesh 
of the matrix.
The USP gives the specifications for the range of 
percentage of MH released in a 24 h profile. This profile 
range is between 20-40%, 35-55%, 75-85%, and 85-100% 
at 1, 4 10 and 24 h, respectively. These values are reflec-
ted in a k value from 0.23 to 0.39 and n value from 0.3 to 
0.43. For matrix tablets, an n value close to 0.5 indicates 
a diffusion control mechanism and n close to 1.0, erosion 
or relaxation control. The range for n values suggests that 
formulations with diffusion as the dominant mechanism of 
drug release is desirable. Formulations which rendered k 
and n parameters within the USP range and having the best 
fit to the non-linear KP model (R2 > 0.9990) were selected 
as appropriate and shown in Figure 2. Since the USP gives 
a broad range of drug release, 10 formulations fulfilled 
the specifications out of the 69 formulations studied. For 
FIGURE 1 - Release profiles of metformin.HCl from the single 
polymers.
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example, formulations 21, 28, 31, 32, 39, 44, 45, 52, 65 
and 69 had low levels of highly hydrophilic polymers such 
as PVP and carrageenan and high levels of swelling and 
gelling polymers such as ethyl cellulose, sodium alginate, 
HPMC and gum arabic. 
Mathematical modeling
The least squares method rendered a cubic model for 
the mixture design with the best fit for k and n. Thus, the 
results of the model statistics show R2 values of 0.9645 
and 0.9664 for both response models, which indicate a 
good correlation between the experimental and predicted 
responses (Table II). The ANOVA test conducted on the 
cubic regression models indicates that the mixture design 
developed for the two responses were significant and 
adequate.
The cubic model fitting evaluates the effect of the 
polymers to obtain an estimate of the coefficients. These 
coefficients and their significance are shown in Table III. 
The cubic equations comprise the coefficients for first or-
der main effects and their interaction terms. The sign and 
TABLE II - ANOVA table for k and n as result of cubic model
Response Source Sum of squares Degrees of 
freedom
Mean squares F-ratio p-value
k Cubic model 7.42915 55 0.135075 39.63 <0.01
Error total 0.27947 82 0.003408
Total (corregido) 7.70862 137 R2 0.9637
n Model 3.07841 55 0.055971 43.89 <0.01
Error total 0.10457 82 0.001275
Total (corregido) 3.18297 137 R2 0.9671
k= release rate constant; n= release order
FIGURE 2 - Release profiles of metformin.HCl for formulations 
which fulfilled USP34/NF29 specifications.
magnitude of the main effects signify the relative influence 
of each factor on the response, i.e., average result of chan-
ging one factor at a time from its low to high value. The 
interaction terms show how the response changed when 
two factors were simultaneously changed. 
In the coefficients table a negative sign signifies an 
antagonistic effect, while a positive sign signifies a syner-
gistic effect to the responses. It can be observed in Table 
III that the release rate increased greatly with increasing 
levels of PVP and carrageenan, whereas it decreased with 
increasing levels of sodium alginate, whereas gum arabic 
had a minor effect. Most of the second and third order 
interaction terms had a negative effect on release rate 
especially if PVP was present.
On the other hand, the release order (n) was found 
be positively influenced by increasing levels of the 
polymers studied, especially for HPMC. If this material 
is formulated alone with the drug a Fickian diffusion 
mechanism is expected. Conversely, if the matrix is 
mainly composed of PVP or carrageenan an anomalous 
release is expected. 
Figure 3A and B show the mixture surface plots for 
k and n of three components at a time, while keeping the 
other three components constant. The k parameter incre-
ases when the PVP component increases, whereas for EC 
and HMPC it fluctuates showing a saddle shape. The n 
parameter on the other hand, increased with increasing 
amount of EC and HPMC, yet decreased with increasing 
amounts of PVP. Figure 3C shows the surface plot for k 
having the components C, SA and AG. Overall, it had a 
butterfly shape. In this case, the k parameter increased 
when the amount of GA increased, whereas it decreased 
forming a valley and then increased when the amount of 
C and SA increased. Figure 3D shows the surface plot for 
the n parameter having a saddle shape. This parameter 
remained virtually unchanged with increasing amounts of 
GA. However, when the amount of C and SA increased, 
n reached a saddle point followed by a sharp decrease.
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TABLE III - Cubic model fitting results for k and n
Parameter K N
Coeff. SE t statistic p-value Coeff. SE t statistic p-value
PVP 0.98 0.1 9.80 <0.01 0.004 0.06 0.07 <0.01
EC 0.62 0.1 6.20 <0.01 0.16 0.06 2.67 <0.01
HPMC 0.24 0.1 2.40 <0.01 0.45 0.06 7.50 <0.01
C 0.79 0.1 7.90 <0.01 0.07 0.06 1.17 <0.01
AS 0.31 0.1 3.10 <0.01 0.37 0.06 6.17 <0.01
GA 0.31 0.1 3.10 <0.01 0.39 0.06 6.50 <0.01
PVP*GA -1.27 0.2 -6.33 0.00 0.77 0.1 6.35 <0.01
PVP*EC 0.95 0.2 4.75 <0.01 -0.39 0.1 -3.18 <0.01
PVP:SA 0.51 0.2 2.54 0.01 -0.40 0.1 -3.29 <0.01
EC*HPMC -1.26 0.2 -6.33 0.00 0.75 0.1 6.12 <0.01
EC*GA -0.47 0.2 -2.35 0.02 0.37 0.1 2.97 <0.01
HPMC:C -0.99 0.2 -4.92 0.00 0.70 0.1 5.67 <0.01
C:GA -0.96 0.2 -4.80 0.00 0.64 0.1 5.22 <0.01
PVP*EC*HPMC -9.71 1.3 -7.34 0.00 4.82 0.8 5.96 <0.01
PVP*EC*C -5.04 1.3 -3.81 0.00 3.15 0.8 3.89 <0.01
PVP*EC*SA 7.64 1.3 6.00 0.00 -5.61 0.8 7.20 <0.01
PVP*HPMC*SA -9.42 1.4 6.51 0.00 6.86 0.9 7.75 <0.01
PVP*HPMC*GA 4.26 1.4 2.96 0.00 -2.12 0.9 -2.41 0.02
PVP*C*GA -4.80 1.4 -3.33 0.00 2.84 0.9 3.23 <0.01
EC*HPMC*C -6.98 1.4 -4.95 0.00 6.68 0.9 7.73 <0.01
EC*HPMC*GA 4.89 1.6 3.06 0.00 -2.95 1.0 -2.35 0.02
HPMC*C*GA 5.05 2.2 2.30 0.02 -0.34 1.0 -0.35 0.73
HPMC*SA*GA -4.46 2.1 -2.09 0.04 1.57 1.3 1.21 0.23
C*SA*GA -9.89 2.1 -4.64 0.00 8.93 1.3 6.85 <0.01
SE = standard error; Coeff. = Coefficient
Validation of the cubic model results
A numerical optimization technique using the 
desirability approach was employed to develop a new 
formulation with the desired responses. The optimization 
was done with the constraints for n of 0.36 and k of 0.31 
as the goals to find the optimum composition of polymers 
in the new formulation. Further, check points of the 10 
formulations which fulfilled the USP requirements were 
conducted. The experimental responses were compared 
to those predicted by the cubic models and the results 
are shown in Table IV. A high correlation was observed 
between the predicted and observed response variables 
(> 98%). The optimized formulation is composed of 68.7% 
ethylcellulose and ~6.3% of all other polymers, rendering 
k and n values of 0.28 and 0.41, respectively.
CONCLUSION
The magnitude of release rate and release order 
depended on the interactions between the drug, polymers 
and the medium employed. Hydrophilic matrixes of MH 
were successfully prepared by wet granulation followed by 
tableting. The effect of type of polymer and its concentra-
tion was evaluated using a mixture design. Formulations 
containing high levels of PVP presented a burst effect on 
the release rate and the release mechanism was anomalous. 
Conversely, high levels of HPMC and ethylcellulose were 
desirable to achieve the desirable once-a-day modified 
release profile. Further, high levels of HPMC shifted the 
release mechanism towards a Fickian type. The cubic mo-
del was accurate for predicting the release rate and order 
of release of MH. 
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FIGURE 3 - Mixture surface plots for k and n. A. and B. SA, C and GA are held at 0.0626. C and D. PVP, HPMC and EC are held 
at 0.0626, 0.0626 and 0.687, respectively.  
TABLE IV – Validation runs for k and n
Formulation Experimental values Predicted values R2
k n k N
Target* 0.310 0.360 0.276 0.410 0.9826
F21 0.359 0.309 0.312 0.360 0.9954
F28 0.359 0.322 0.312 0.362 0.9973
F31 0.282 0.402 0.308 0.36 0.9977
F32 0.291 0.387 0.309 0.360 0.9990
F39 0.277 0.391 0.312 0.360 0.9987
F44 0.269 0.400 0.308 0.366 0.9985
F45 0.338 0.346 0.311 0.360 0.9994
F52 0.294 0.388 0.314 0.360 0.9989
F65 0.313 0.380 0.312 0.360 0.9995
F69 0.285 0.398 0.306 0.360 0.9981
*The target formulation was that which renders k and n values of 0.31 and 0.36, respectively
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